In the wake of the latest clinical guidelines - mineralocorticoid receptor antagonists in the treatment of chronic heart failure

In the wake of the latest clinical guidelines - mineralocorticoid receptor antagonists in the treatment of chronic heart failure

Chronic heart failure (CHF) today is a heart condition with the least favourable prognosis. Over the past 10-15 years, in addition to strong rationale supporting the effectiveness of angiotensin-converting enzyme inhibitors (ACEI), results of use were obtained for angiotensin receptor blockers (ARB)...

Full description

Bibliographic Details
Main Authors:	I. V. Zhirov, Y. F. Osmolovskaya, S. N. Tereschenko
Format:	Article
Language:	Russian
Published:	Remedium Group LLC 2015-12-01
Series:	Медицинский совет
Subjects:	ингибитор ангиотензинпревращающего фермента хроническая сердечная недостаточность эплеренон инспра angiotensin-converting enzyme inhibitor chronic heart failure eplerenone
Online Access:	https://www.med-sovet.pro/jour/article/view/152

Similar Items

A SELECTIVE ANTAGONIST OF MINERALOCORTICOID RECEPTOR EPLERENONE IN CARDIOLOGY PRACTICE
by: B. B. Gegenava, et al.
Published: (2015-09-01)

Pharmacogenetics in treatment of anthracycline-induced cardiotoxicity in women without prior cardiovascular diseases
by: E. V. Grakova, et al.
Published: (2023-01-01)

Clinical application of mineralocorticoid receptor antagonists in chronic heart failure
by: MG Bubnova
Published: (2014-12-01)

Protivoishemicheskoe, antiaritmicheskoe i sosudistoe deystvie ingibitora angiotenzinprevrashchayushchego fermenta zofenoprila v eksperimente
by: E V Shlyakhto, et al.
Published: (2006-06-01)

ADVANTAGES OF COMBINATION THERAPY OF HYPERTENSION WITH CALCIUM CHANNEL BLOCKER AND ANGIOTENSIN-CONVERTING ENZYME INHIBITOR IN PATIENTS WITH IMPAIRED RENAL FUNCTION
by: N. A. Dzhaiani
Published: (2015-09-01)

COMBINATION OF ANGIOTENSIN-CONVERTING ENZYME INHIBITORS AND CALCIUM CHANNEL BLOCKERS IN HYPERTENSIVE PATIENTS WITH HEART FAILURE AND PRESERVED SYSTOLIC FUNCTION: IS THERE A PLACE FOR AN INFORMED CHOICE?
by: I. V. Zhirov, et al.
Published: (2013-12-01)

PHARMACOECONOMIC ASPECTS OF EPLERENONE USAGE IN CHRONIC HEART FAILURE
by: Yu. M. Lopatin, et al.
Published: (2015-08-01)

Cardiorenal syndrome in patients with heart failure as a stage of the cardiorenal continuum (part 2): prognosis, prevention and treatment
by: E. V. Reznik, et al.
Published: (2019-03-01)

Levels of cytokines and C-reactive protein as treatment effectiveness criteria in patients with coronary heart disease and chronic heart failure
by: E. Yu. Sazhina, et al.
Published: (2008-06-01)

An angiotensin-converting enzyme inhibitor in the combination treatment of rheumatoid arthritis
by: E. B. Komarova, et al.
Published: (2017-09-01)

Differential approach in selecting beta-adrenoblocker therapy for patients with chronic heart failure and anaemia
by: T. M. Uskach, et al.
Published: (2012-04-01)

Kombinirovannaya terapiya ingibitorom angiotenzinprevrashchayushchego fermenta i diuretikom
by: I E Chazova, et al.
Published: (2006-06-01)

Differential beta-adrenoblocker therapy in chronic heart failure
by: S. N. Tereshchenko, et al.
Published: (1970-01-01)

Changes of myocardial fibrosis markers with the use of beta-blockers and mineralocorticoid receptor antagonists in patients with heart failure with mid-range ejection fraction of ischemic origin
by: O. A. Osipova, et al.
Published: (2021-11-01)

The first Russian register of patients with chronic heart failure and atrial fibrillation (RIF-CHF): study design
by: S. N. Tereshchenko, et al.
Published: (2015-12-01)

Spirapril – a modern ACE inhibitor
by: V. M. Gorbunov
Published: (2005-06-01)

БЕЗОПАСНОСТЬ ИНГИБИТОРОВ АНГИОТЕНЗИНПРЕВРАЩАЮЩЕГО ФЕРМЕНТА В РАННИЕ СРОКИ БЕРЕМЕННОСТИ
by: Ф. И. Белялов
Published: (2015-02-01)

Фармакоэкономический анализ применения левосимендана у больных с тяжёлой декомпенсированной хронической сердечной недостаточностью
Published: (2018-06-01)

CHRONIC HEART FAILURE AND IRON-DEFICIENT ANEMIA
by: M. V. Melnik, et al.
Published: (2015-12-01)

KEY PATHOGENETIC ASPECTS AND CLINICAL RELEVANCE OF MECHANICAL DYSSYNCHRONY
by: Yu. V. Stavtseva, et al.
Published: (2015-09-01)

EFFECT OF MITRAL REGURGITATION ON CHRONIC HEART FAILURE COURSE AND STRUCTURE-FUNCTIONAL HEART STATE
by: V. N. Larina, et al.
Published: (2016-01-01)

Pathogenesis of chronic heart failure: change of dominating paradigm
by: V. V. Kalyuzhin, et al.
Published: (2007-12-01)

NEW OPPORTUNITIES FOR PREVENTIVE THERAPY WITH STATINS DURING CHD PATIENTS’ REHABILITATION, WITH CLINICAL SIGNS OF MODERATE CHF: EFFECTIVENESS OF ROSUVASTATIN AND EZETIMIBE
by: N. I. Tarasov, et al.
Published: (2016-06-01)

Physical training – modulator of peripheral factors for chronic heart failure development
by: A. S. Noskova, et al.
Published: (2007-02-01)

Echocardiographic characteristics of patients with ischemic and non-ischemic chronic heart failure with reduced ejection fraction
by: N. N. Ilov, et al.
Published: (2022-10-01)

NEW EMPHASES ON THE STUDY OF THE PATHOGENESIS OF CHRONIC HEART FAILURE WITH PRESERVED EJECTION FRACTION: FOCUS ON INFLAMMATORY MARKERS
by: O. M. Drapkina, et al.
Published: (2015-09-01)

ACE inhibitors in arterial hypertension treatment among various clinical groups
by: O. D. Ostroumova, et al.
Published: (1970-01-01)

ANGIOTENSIN CONVERTING ENZYME INHIBITORS IN ACUTE MYOCARDIAL INFARCTION: WHEN TO START THERAPY AND WHICH DRUG TO USE?
by: S. Y. Martsevich, et al.
Published: (2015-12-01)

Primenenie ingibitorov angiotenzinprevrashchayushchego fermenta v lechenii arterial'noy gipertonii
by: A S Galyavich
Published: (2006-06-01)

Chronic heart failure risk factors in patients with chronic kidney pathology
by: O. E. Ilyicheva
Published: (2008-02-01)

ЦИСТАТИН С В ДИАГНОСТИКЕ ХРОНИЧЕСКОЙ БОЛЕЗНИ ПОЧЕК У БОЛЬНЫХ С ХРОНИЧЕСКОЙ СЕРДЕЧНОЙ НЕДОСТАТОЧНОСТЬЮ В КЛИНИЧЕСКОЙ ПРАКТИКЕ
by: Т. Е. Кузнецова, et al.
Published: (2014-12-01)

SELECTION OF THE OPTIMAL ANTIHYPERTENSION TREATMENT IN PATIENTS WITH CHRONIC HEART FAILURE WITH THE SIGNS OF CHRONIC KIDNEY DISEASE
by: N. Yu Borovkova, et al.
Published: (2016-12-01)

Оптимизация фармакотерапии хронической сердечной недостаточности с помощью отечественного β-адреноблокатора проксадола
Published: (2018-06-01)

ВЛИЯНИЕ АПОПТОЗА НА ТЕЧЕНИЕ ХРОНИЧЕСКОЙ СЕРДЕЧНОЙ НЕДОСТАТОЧНОСТИ
by: Ye. N. Berezikova, et al.
Published: (2015-10-01)

HEART RATE-LOWERING THERAPY IN THE TREATMENT OF CHRONIC HEART FAILURE
by: S. V. Shalaev, et al.
Published: (2015-09-01)

Russian National Research Medical University named after N.I. Pirogov, Moscow
by: V. N. Larina, et al.
Published: (2015-09-01)

ROLE OF THE METABOLITE THERAPY FOR THE TREATMENT OF CHRONIC HEART FAILURE
by: L. N. Maksimova, et al.
Published: (2015-09-01)

ПРОБЛЕМА ОТСУТСТВИЯ ОТВЕТА НА КАРДИОРЕСИНХРОНИЗАЦИОННУЮ ТЕРАПИЮ ПРИ ХРОНИЧЕСКОЙ СЕРДЕЧНОЙ НЕДОСТАТОЧНОСТИ
by: S. I. Stupakov
Published: (2015-10-01)

RATIONAL CHOICE OF Β-ADRENOBLOCKERS IN CHRONIC HEART FAILURE THERAPY
by: M. L. Maximov
Published: (2015-12-01)

ANGIOTENSIN CONVERTING ENZYME INHIBITORS IN MANAGEMENT OF PATIENTS WITH CHRONIC HEART FAILURE
by: S. N. Tereshchenko, et al.
Published: (2016-01-01)